NCT04720534Phase 2Completed

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-03-09Actual
Enrollment · participants229Actual
Source updated2026-03-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview